RT Journal Article
SR Electronic
T1 The oligometastatic paradigm and the role of radiotherapy
JF Clinical Medicine
JO Clin Med
FD Royal College of Physicians
SP 61
OP 64
DO 10.7861/clinmed.2022-0559
VO 23
IS 1
A1 Killian Nugent
A1 James Good
YR 2023
UL http://www.rcpjournals.org/content/23/1/61.abstract
AB Most cancer-related deaths are due to metastatic disease. There is now an emerging evidence base suggesting that a subgroup of metastatic patients benefit significantly from local resection (surgery) or ablation (stereotactic ablative body radiation, SABR) of their metastatic sites. These patients are in what has been termed the ‘oligometastatic state’, a transitional window between local and disseminated disease where locally ablative, metastasis-directed therapy prolongs progression-free survival, improves overall survival and sometimes achieves cure. Appropriately selecting those who fit this oligometastatic phenotype, while integrating advances in ablative technologies such as SABR with modern systemic treatments, is an evolving challenge for oncologists.